Need a quote from a Motley Fool analyst? Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly special: a differentiated platform pioneering the integration of large-scale ...

NYU Langone’s decision comes amid Trump administration threats to cut funding to providers who treat trans youth NYU Langone Health, one of New York City’s major hospital networks, announced this week ...

The NASA Mars Sample Return program is encountering resistance from the planetary science community due to proposed budget language that would terminate the current mission framework. In early January ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

View post: Milwaukee’s ‘Handy’ 100-Piece Impact Driver Bit Set Is on Sale at Amazon for 30% Off Porsche faces a myriad of problems in China. For one, the brand’s cars are somewhat niche by design, ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...

Rachel Ho is a rising 10th-grader at Langley High School in McLean. She loves writing and thinks she might want to follow in her mother’s footsteps and study at the University of Virginia. To get a ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...